Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05459168 · ClinicalTrials.gov registry record · NA

Development of Calm for Cancer Prototype Mobile App

A NA study of Cancer, sponsored by Calm.com.

Completed
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT05459168: Completed NA study of Cancer, sponsored by Calm.com.

NCT05459168 is a NA study of Cancer that has completed, run by Calm.com. The registered enrollment target is 50 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT05459168, a NA study of Cancer, has completed, sponsored by Calm.com.

COMPLETED
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

Using the IDEAS (Integrate, Design, Assess, and Share) framework, the investigators will conduct the following aims: Specific Aim 1: Using two focus groups, the investigators will INTEGRATE formative work, the social cognitive theory, and perspectives from the experienced-user advisory committee (N=20) who will use the current Calm platform to identify design content and features for a standalone cancer-specific app prototype leveraging the commercial infrastructure of the Calm platform. The advisory committee will consist of both cancer patients/survivors (n=10; 5 of each) and health care providers (n=10). Specific Aim 2: DESIGN a meditation app prototype tailored to cancer patients/survivors unique needs including content related to cancer-related experiences, emotions, symptoms, physical and psychological needs, cancer-specific symptom self monitoring, social support and sense of belonging within the app and through Facebook. Specific Aim 3: ASSESS (i.e., beta-test) the prototype's form and function with cancer patients/survivors (N=30). The investigators will use Bowen's feasibility model to determine via surveys and interviews: (a) acceptability (satisfaction, perceived appropriateness, perceived positive/negative effects); (b) demand (use of the app, interest or intention to use); (c) practicality (how it makes them feel, ease of use); (d) adaptation (suggestions for modifications to improve performance for cancer patients/survivors); and (e) integration (how can the app be integrated into the cancer "system") Feasibility benchmarks: \>80% of cancer patients/survivors will accept the prototype, demand the prototype for themselves and other cancer patients/survivors, and find it practical. Data from Aim 3 will guide refinement of the prototype to be tested in a fully powered RCT to establish long term engagement (Phase 2). This work will result in an evidence based, cancer-specific meditation app through a commercial platform that can be scaled and sold at d

Primary Outcome

Acceptability is defined as satisfaction, intent to continue to use, perceived appropriateness according to Bowen and colleagues feasibility criteria.

Conditions Studied

Interventions

  • OTHER Calm Meditation Smartphone App Feedback
  • OTHER Cancer-Specific Meditation App Prototype Design
  • DEVICE Cancer-Specific Meditation App Prototype

Study Locations (1)

California

  • Calm, Inc. - San Francisco

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2021-03-01
Est. Completion 2022-03-15
Phase NA
Calm.com

3 total trials

What the finished NCT05459168 record still lists

NCT05459168 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 3 interventions - of which Calm Meditation Smartphone App Feedback is the first listed.

NCT05459168 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT05459168 about?

NCT05459168 is a clinical study titled "Development of Calm for Cancer Prototype Mobile App". Using the IDEAS (Integrate, Design, Assess, and Share) framework, the investigators will conduct the following aims: Specific Aim 1: Using two focus groups, the investigators will INTEGRATE formative work, the social cognitive theory, and perspectives from the experienced-user advisory committee (N...

What is the current status of trial NCT05459168?

This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2021-03-01. Estimated completion is 2022-03-15.

What conditions does trial NCT05459168 study?

This clinical trial studies the following conditions: Cancer.

What interventions are being tested in trial NCT05459168?

The interventions under investigation include: Calm Meditation Smartphone App Feedback (OTHER), Cancer-Specific Meditation App Prototype Design (OTHER), Cancer-Specific Meditation App Prototype (DEVICE).

Who is sponsoring clinical trial NCT05459168?

This trial is sponsored by Calm.com, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05459168 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05459168's enrollment target sits among peer trials

50 422nd of 615 higher than 179 of 615 other Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05459168, the US trial registry maintained by the National Library of Medicine. NCT05459168 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.